Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. - Wikidata - wikimedia - TriplyDB

Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study.

Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study.

http://www.wikidata.org/entity/Q33363068

about

Exenterative surgery for recurrent gynaecological malignancies Exenterative surgery for recurrent gynaecological malignancies Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma Adjuvant chemotherapy for endometrial cancer after hysterectomy Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma Practice guidelines for management of uterine corpus cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study.Chemotherapy intensity and toxicity among black and white women with advanced and recurrent endometrial cancer: a Gynecologic Oncology Group Study An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study.A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.Sequential chemotherapy and radiotherapy as sandwich therapy for the treatment of high risk endometrial cancer Feasibility study of paclitaxel plus carboplatin in patients with endometrial cancer: a Japan Kanto Tumor Board study (JKTB trial).SERPINA3 promotes endometrial cancer cells growth by regulating G2/M cell cycle checkpoint and apoptosis.Endometrial cancer: what is new in adjuvant and molecularly targeted therapy?Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?: a Gynecologic Oncology Group ancillary data analysis.Platinum covalent shell cross-linked micelles designed to deliver doxorubicin for synergistic combination cancer therapy A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia.Promising novel therapies for the treatment of endometrial cancer Controversies in the management of endometrial cancer.Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.DNA damage detected with gammaH2AX in endometrioid adenocarcinoma cell lines.Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma: results of a prospective phase 2 trial.Terpenoids from Zingiber officinale (Ginger) induce apoptosis in endometrial cancer cells through the activation of p53 Etoposide incorporated into camel milk phospholipids liposomes shows increased activity against fibrosarcoma in a mouse model Coadministration of doxorubicin and etoposide loaded in camel milk phospholipids liposomes showed increased antitumor activity in a murine model.Endometrial carcinoma: a review of chemotherapy, drug resistance, and the search for new agents Deviation from intention to treat analysis in randomised trials and treatment effect estimates: meta-epidemiological study.Appendiceal metastasis 10 years following 'curative' resection for low-grade primary endometrial carcinoma Effect of the molecular targeted drug, erlotinib, against endometrial cancer expressing high levels of epidermal growth factor receptor Investigating the relative efficacies of combination chemotherapy of paclitaxel/carboplatin, with or without anthracycline, for endometrial carcinoma ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up.A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial.A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study.Progress in gynecologic cancer research: the Gynecologic Oncology Group experience Glycogen synthase kinase 3β inhibition as a therapeutic approach in the treatment of endometrial cancer.Present status and future direction of clinical trials in advanced endometrial carcinoma Molecular target therapies in endometrial cancer: from the basic research to the clinic.Current treatment strategies for endometrial cancer.Current treatment of metastatic endometrial cancer.

P2860

Q24200357-40E8FC2A-32B2-4A91-9B13-76A3841DB5B3 Q24200596-9F22617B-D7FA-4694-941C-96F27F86651B Q24201586-14C7EF78-23F6-49A7-8408-57931DEF2C6A Q24236277-1D74C7D7-672F-4B89-BA56-4D83A9387DE2 Q24246360-E407F487-837F-4D38-94EA-57B515CC8BCE Q28069514-BB5A45FA-DCE4-41C1-AE73-F9FDDD6FFF7F Q30389289-16ABB8DC-B7E9-4243-941D-AEB737722429 Q30433480-7057475D-1F3D-49C6-8B4A-71314762D1C9 Q30439393-4EBC0AE5-B679-4876-B626-E43E2C84E195 Q30442540-C7958FCC-F4DA-4018-84A5-F46C9E832C9D Q33399852-D90782B2-D1EA-4D4F-8C6F-69AB036E6C3E Q33401454-3E38ABAA-D8C0-4673-A7A7-AF67A5D247C9 Q33582882-DAD924EA-F489-4259-B416-D70F6ADFC74C Q33633962-3E3D1582-B7D0-455B-8E19-C5FA9494D755 Q33671891-4F3E4072-EC95-4492-A4A0-66576EEFA42C Q33713159-689E428F-3AF6-4056-BAD0-243BBC9141CB Q33742211-BC292727-14B2-4FEB-9625-203F914EBD37 Q33920661-B60258A4-0B54-4297-A45D-5857A6F62E2A Q33960860-0A40EF45-0769-4162-AFD8-39F7717653D4 Q34215306-22C263C3-9B8C-4D9C-B42E-3F18B3C5C2D2 Q34275075-4B263B3D-61FC-46B3-AFF8-461D3500AC82 Q34409341-55C4F247-517A-4C90-9A89-9B01C2618064 Q34541738-49B0705E-2E42-44DA-8E17-B3C8D881040E Q35187801-E89E8AF4-85C3-454D-B328-56441D9DEA95 Q35491314-110E4CD0-981D-41A3-ADCA-5DAD9BF736D4 Q35583750-3F009979-8017-467D-9292-68FBCE1D97DF Q35654012-F817A763-0108-4B46-B8CB-9BC6EDB72B5C Q35863554-E04D7773-271F-4BC1-B57E-E80FC54D06A2 Q35870242-26237114-5507-4E2C-BE40-4A43AF9C45D8 Q35886274-EA20D4CB-5BBE-4A4A-A6DA-3226C0DFD9DB Q36372293-DE90A1E8-A18F-4E8C-BEE4-7D209C892279 Q36407018-BE3FEF27-8AB1-4301-9449-17AD8C2AB60C Q36598756-7B06CCC7-AC40-4DE7-854C-CE0D49AC19C4 Q36615520-323FCA20-345E-4401-AE9B-42E75D427DE6 Q36979840-E7BEE430-2EA0-428C-9A26-87ADB590E006 Q37139199-992BDACD-1829-447E-A87A-827E85C67139 Q37177663-B011F4EA-DC31-4130-B0C1-DED3DD32CB7B Q37196543-323ECDCF-E900-42F0-818A-35E24440D05A Q37202781-1892894D-071A-412F-9B7F-5F8A894B7633 Q37349633-61684285-2F02-4F49-892D-07BCD84FD580

P2860

Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study.

http://www.wikidata.org/entity/Q33363068

description

2004 nî lūn-bûn

@nan

2004 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Phase III trial of doxorubicin ...... ecologic oncology group study.

@ast

Phase III trial of doxorubicin ...... ecologic oncology group study.

@en

type

label

Phase III trial of doxorubicin ...... ecologic oncology group study.

@ast

Phase III trial of doxorubicin ...... ecologic oncology group study.

@en

prefLabel

Phase III trial of doxorubicin ...... ecologic oncology group study.

@ast

Phase III trial of doxorubicin ...... ecologic oncology group study.

@en

P1433

Q33363068-93599144-04D3-4A44-84DF-4F764B65DCA0

P1476

Q33363068-66A2A3FE-5989-4AE8-BEDC-7B0266EEAC27

P2093

Q33363068-318BBE95-14CA-4749-9EBF-6741811DE137

Q33363068-56C7411B-BF4D-4E48-A49C-04BA9EA2A8E3

Q33363068-83D08113-C51D-4AA7-A1B9-F3B45CDCE9DC

Q33363068-8F5BCA69-CC62-4D63-B429-846D3C0994EC

Q33363068-C5D84F61-7B13-4B63-9513-B819C887E864

Q33363068-CA022778-59B4-4B26-AE2F-03AD667E8CAF

Q33363068-DBA3B1FD-E4B7-4D05-8610-AC8826A7DE65

P304

Q33363068-885A6998-A0E2-4A23-A80D-872C6E2A2E1E

P31

Q33363068-C13E78C1-1DF3-4C6C-96AA-2254E793CEC6

P3181

Q33363068-B9BC8799-F42B-4752-82E0-EF529B4A8FC8

P356

Q33363068-D85EB67D-E003-4BCA-BD87-0A162B337D17

P407

Q33363068-8714A5F7-0A4C-471C-B335-39873148043C

P433

Q33363068-2C90EF0F-5E6E-457D-9356-6AC513E7ADC2

P478

Q33363068-39F1B23E-31CD-4CC8-8F79-9444C33CEC3C

P577

Q33363068-1A200369-EB92-4F77-85D2-FA4551ADD853

P698

Q33363068-52042EA6-B9CD-49E4-B720-DA03CA8CEE77

P921

Q33363068-2C57287D-1035-4140-ACCF-60B8F10E4BC0

P3181

P356

JCO.2004.02.088

P1433

Journal of Clinical Oncology

P1476

Phase III trial of doxorubicin ...... ecologic oncology group study.

@en

P2093

Brent DuBeshter

http://www.w3.org/2001/XMLSchema#string

Howard D Homesley

http://www.w3.org/2001/XMLSchema#string

J Tate Thigpen

http://www.w3.org/2001/XMLSchema#string

John Malfetano

http://www.w3.org/2001/XMLSchema#string

Mark F Brady

http://www.w3.org/2001/XMLSchema#string

Robert A Burger

http://www.w3.org/2001/XMLSchema#string

Shu Liao

http://www.w3.org/2001/XMLSchema#string

P304

3902-3908

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

523

http://www.w3.org/2001/XMLSchema#string

P356

10.1200/JCO.2004.02.088

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P577

2004-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15459211

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial